Get the Stockscreener App
51.99
0.78%
-0.41
After Hours:
51.99
Xenon Pharmaceuticals Inc stock is traded at $51.99, with a volume of 709.94K.
It is down -0.78% in the last 24 hours and down -4.41% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$52.40
Open:
$52.49
24h Volume:
709.94K
Relative Volume:
0.58
Market Cap:
$5.03B
Revenue:
$7.50M
Net Income/Loss:
$-383.17M
P/E Ratio:
-11.05
EPS:
-4.7048
Net Cash Flow:
$-307.84M
1W Performance:
-1.52%
1M Performance:
-4.41%
6M Performance:
+20.91%
1Y Performance:
+62.37%
1-Day Range:
$51.54
$52.68
1-Week Range:
$51.11
$53.76
52-Week Range:
$30.00
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
51.99 | 5.07B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate - Yahoo Finance
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Fiera Capital Corp Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) director Cannon sells 1,190 shares under 10b5-1 tax plan - Stock Titan
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade - Stock Titan
[144] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
Xenon Pharmaceuticals (XENE) director receives new RSUs, options and RSU vesting - Stock Titan
Xenon Pharmaceuticals (XENE) director awarded RSUs, options and exercises vested RSUs - Stock Titan
Xenon Pharmaceuticals (XENE) director receives RSUs, options and nets vested shares - Stock Titan
Xenon Pharmaceuticals (XENE) investors approve 2026 equity plan and pay votes - Stock Titan
Xenon Pharmaceuticals (XENE) director exercises RSUs and gets new option award - Stock Titan
Xenon Q1 earnings match estimates, pipeline development in focus - MSN
Xenon Pharmaceuticals Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Xenon Pharmaceuticals Inc. Rings the Opening Bell - Nasdaq
Wells Fargo Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Assessing Xenon Pharmaceuticals (XENE) Valuation After A Recent Pullback And Strong Multi Year Returns - Sahm
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
XENE Q1 2026 Earnings: EPS Beat Amid Continued Clinical Development FocusOne-Time Gain Impact - newsline.com
J.P. Morgan Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $82 - Moomoo
XENE Maintains Overweight Rating -- Price Target Raised to $82.0 - GuruFocus
Xenon Pharmaceuticals (XENE) Edges Higher Amidst Neutral TradingFactor ETF Flow - thelegaladvocate.com
Trading the Move, Not the Narrative: (XENE) Edition - Stock Traders Daily
Xenon Pharmaceuticals (XENE) Holds Near Support Amid Modest PullbackVolatility Skew - thelegaladvocate.com
JPMorgan Raises its Price Target on Xenon Pharmaceuticals (XENE) - Insider Monkey
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
5 Best Performing Canadian Stocks So Far in 2026 - Insider Monkey
A Look At Xenon Pharmaceuticals (XENE) Valuation After Strong Long Term Returns And Recent Momentum Cooldown - Sahm
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing - AOL.com
Which Is a Better Investment, Sarepta Therapeutics, Inc. or Xenon Pharmaceuticals Inc. Stock? - AAII
Xenon Pharmaceuticals stock (CA98420N1050): epilepsy data and capital raise put biotech in focus - AD HOC NEWS
DNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Janus Henderson reports 4.5% stake in Xenon Pharmaceuticals (XENE) filing - Stock Titan
Xenon Pharmaceuticals (NASDAQ: XENE) shows 5.78M-share holding, 6.26% - Stock Titan
Driehaus files Schedule 13G/A disclosing 4.87% in Xenon (XENE) - Stock Titan
XENE: Azetukalner’s strong efficacy and novel mechanism set the stage for a major epilepsy market launch - TradingView
Xenon Pharmaceuticals stock (CA98420N1050): Director exercises options for 3,500 shares - AD HOC NEWS
Xenon Pharmaceuticals (XENE) director exercises options, now holds 10,641 shares - Stock Titan
XENE Maintained by JP Morgan -- Price Target Raised to $80.00 - GuruFocus
Xenon Pharmaceuticals Is Maintained at Overweight by JP Morgan - Moomoo
Xenon anticipates AZK NDA in Q3 2026 amid launch timing at end of 2027 or early 2028 - MSN
Equities Analysts Set Expectations for XENE Q2 Earnings - MarketBeat
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway - Yahoo Finance
Insiders At Xenon Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness - Moomoo
Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative? - Yahoo Finance
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xenon Pharmaceuticals Inc Stock (XENE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cannon Gillian | Director |
Jun 05 '26 |
Sale |
53.14 |
1,190 |
63,237 |
1,455 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):